Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home Newsroom
In the News

December 1, 2014
Telesta Therapeutics Announces Key Clinical & Corporate Updates

November 25, 2014
BIONICHE LIFE SCIENCES INC. REBRANDS AS TELESTA THERAPEUTICS INC.

Investors

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.


Newsroom

Human Health

October 2014

10/10/14
Bioniche Life Sciences Inc. to Publish Comprehensive Phase 3 Clinical Trial Results In The Journal of Urology

August 2014

19/08/14
Bioniche Announces Q1/2015 Timeline for the Filing of a Biologics License Application for Marketing Approval of MCNA in the United States

July 2014

29/07/14
Bioniche Announces Submission of Orphan Drug Designation Application for MCNA in the United States

18/07/14
Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States

December 2013

04/12/13
Primary and Long-Term Illness Related to E. coli O157 Costs $403.9 Million per Year in Canada

July 2013

08/07/13
Health Canada Provides Direction to Bioniche Life Sciences Inc. Regarding New Drug Submission Filing

April 2013

01/04/13
Bioniche Life Sciences Inc. Regains Sponsorship of Urocidin™

March 2013

07/03/13
Bioniche Life Sciences Inc. Reorganizes One of its Business Units

January 2013

03/01/13
Bioniche Life Sciences Inc. Provides an Update on the Return of Urocidin™ Global Rights

December 2012

21/12/12
Endo Pharmaceuticals Returns Urocidin™ Global Rights to Bioniche Life Sciences Inc.

November 2012

05/11/12
Bioniche Life Sciences Inc. Announces Discontinuation of Current Phase III Clinical Trial with Urocidin™

15/11/11
Bioniche Life Sciences Inc. Congratulates Dr. Alvaro Morales on his Appointment as Member of the Order of Canada

May 2011

17/05/11
Urocidin™ Phase III Clinical Trial Results Presented at AUA Conference in Washington, D.C.

February 2011

18/02/11
Urocidin™ Phase III Clinical Trial Results To Be Presented At EAU and AUA Conferences

17/02/11
First Patient Enrolled In Second Phase III Clinical Trial Of Urocidin™

15/02/11
Vaccinating Cattle to Protect Human Health a Topic for First International One Health Congress

November 2010

17/11/10
Urocidin Phase III Trial Results Trigger Milestone Payment to Bioniche from Endo

August 2010

20/08/10
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010

February 2010

12/02/10
Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights

November 2009

25/11/09
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform

August 2009

24/08/09
Bioniche Phase III Clinical Trial with Urocidin™ Given Continued Green Light by DMC

July 2009

10/07/09
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Inc. Sign Licensing Agreement for UrocidinTM

May 2009

22/05/09
Bioniche Phase III Clinical Trial with Urocidin™ Progressing Well

March 2009

31/03/09
Bioniche Completes Recruitment in First Phase III Clinical Trial with UrocidinTM

February 2009

18/02/09
Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology

November 2008

24/11/08
Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile

17/11/08
Update on Bioniche Phase III Clinical Trial in Bladder Cancer

August 2008

18/08/08
Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well

May 2008

13/05/08
Bioniche Updates re: Mycobacterial Cell Wall Technology Platform

March 2008

04/03/08
Bioniche Receives Fast track Designation for First-Line Bladder Cancer Therapy

February 2008

13/02/08
Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin™

August 2007

16/08/07
Bioniche Provides Update on Refractory Bladder Cancer Trial

May 2007

22/05/07
Data Shows Bioniche Proprietary MCC Technology Effective in Inducing Anticancer Activity in 3 Hours

April 2007

16/04/07
Bioniche Presents Additional Data on the Anticancer Activity of MCC Against Peritoneal Carcinomatosis

November 2006

08/11/06
First Patient Treated in Bioniche Phase III Refractory Bladder Cancer Trial

02/11/06
Bioniche Expands Patent Portfolio with Three New Patents

June 2006

29/06/06
Bioniche Presents Additional Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Human Bladder Cancer Cells

May 2006

24/05/06
Mycobacterial Cell Wall-DNA Complex (MCC) Demonstrates Anticancer Activity in an Animal Model of Colon Cancer

23/05/06
Bioniche Closes Sale of its Proprietary Cystitis Product

04/05/06
U.S. FDA Grants Fast Track Designation for Bioniche Bladder Cancer Product

April 2006

03/04/06
Bioniche Receives FDA Approval to Proceed with Phase III Bladder Cancer Trials

March 2006

27/03/06
Bioniche to Host Bladder Cancer Roundtable

13/03/06
Bioniche Granted First Major Composition Patent for Oligonucleotide Technology

February 2006

07/02/06
U.S. FDA Accepts Part One of Bioniche Program for Phase III Clinical Trials with MCC for Bladder Cancer

July 2005

14/07/05
Bioniche Launches Sotradecol® Injection for Varicose Veins in U.S. Market

June 2005

17/06/05
Bioniche Issues Recall of BetacTM

16/06/05
Bioniche Presents Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Peritoneal (Colon) Cancer

03/06/05
New Studies Demonstrate Immunomodulatory Activity of Bioniche Technology in Dogs

May 2005

26/05/05
Bioniche Granted European Patent for Mycobacterial Cell Wall-DNA Complex (MCC) as Prostate Cancer Treatment

April 2005

18/04/05
Bioniche Presents Data on Prevention and Management of Urinary Tract Infections Using Cystistat®

November 2004

22/11/04
FDA Approves Bioniche Pharma ANDA for Sotradecol Injection for the Treatment of Varicose Veins

09/11/04
Bioniche Discusses Further Details of the Phase III Clinical Trial with Urocidin for the Treatment of Bladder Cancer

July 2004

22/07/04
Bioniche Presents Pre-Clinical Data on Anti-Cancer Agents and Immunomodulatory Molecules at International Congress of Immunology

June 2004

14/06/04
Pharmacoeconomic Study into Use of Suplasyn® Demonstrates Reduced Pain and Cost-Effectiveness in Treatment of Patients with Osteoarthritis of the Knee

May 2004

20/05/04
Bioniche Presents Bladder Cancer Clinical Trial and Research Data to American Urological Association Annual Meeting

March 2004

29/03/04
Bioniche Announces Results of Phase I Prostate Cancer Study


Newsroom

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Human Health
One Health

Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy